サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411877

子宮内膜がん治療市場：治療法、グレード、エンドユーザー別-2024-2030年の世界予測

Endometrial Cancer Treatment Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), Grade (Type I, Type II), End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
子宮内膜がん治療市場：治療法、グレード、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮内膜がん治療市場規模は2023年に84億2,000万米ドルと推計され、2024年には88億7,000万米ドルに達し、CAGR 5.47%で2030年には122億3,000万米ドルに達すると予測されます。

子宮内膜がん治療の世界市場

主な市場の統計
基準年[2023］ 84億2,000万米ドル
予測年[2024］ 88億7,000万米ドル
予測年 [2030] 122億3,000万米ドル
CAGR（%） 5.47%
子宮内膜がん治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは子宮内膜がん治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、子宮内膜がん治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-子宮内膜がん治療市場の市場規模および予測は？

2-子宮内膜がん治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-子宮内膜がん治療市場における技術動向と規制の枠組みは？

4-子宮内膜がん治療市場における主要ベンダーの市場シェアは？

5-子宮内膜がん治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界における1型および2型子宮内膜がんの罹患率
      • 子宮内膜がん治療の採用拡大に向けた政府の取り組み
      • 個別化された標的を絞った子宮がん治療の出現
    • 抑制要因
      • 子宮内膜治療に対する限定的な償還構造
    • 機会
      • 新しい子宮内膜がん治療法を開発するための継続的な調査活動
      • 子宮内膜がん治療薬に対する政府の有利な承認
    • 課題
      • 特定の治療法に関連する規制上のハードルとリスク
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 子宮内膜がん治療市場治療別

  • 化学療法
  • 免疫療法
  • 放射線治療

第7章 子宮内膜がん治療市場：グレード別

  • タイプI
  • タイプⅡ

第8章 子宮内膜がん治療市場：エンドユーザー別

  • 外来手術センター
  • がんセンター
  • 病院とクリニック

第9章 南北アメリカの子宮内膜がん治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の子宮内膜がん治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの子宮内膜がん治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AstraZeneca PLC
    • Bayer AG
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Context Therapeutics Inc.
    • CooperSurgical Inc.
    • Eisai Co., Ltd.
    • Elekta AB
    • F. Hoffmann-La Roche AG
    • General Electric Company
    • GlaxoSmithKline PLC
    • Hologic Inc.
    • Johnson & Johnson Services, Inc.
    • Karyopharm Therapeutics Inc.
    • Koninklijke Philips N.V.
    • LiNA Medical ApS
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Siemens Healthineers AG
    • Takeda Pharmaceutical Company Limited
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ENDOMETRIAL CANCER TREATMENT MARKET DYNAMICS
  • FIGURE 7. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2030 (%)
  • FIGURE 10. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 10. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ENDOMETRIAL CANCER TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-521BAA36EC52

[199 Pages Report] The Endometrial Cancer Treatment Market size was estimated at USD 8.42 billion in 2023 and expected to reach USD 8.87 billion in 2024, at a CAGR 5.47% to reach USD 12.23 billion by 2030.

Global Endometrial Cancer Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.42 billion
Estimated Year [2024] USD 8.87 billion
Forecast Year [2030] USD 12.23 billion
CAGR (%) 5.47%
Endometrial Cancer Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Endometrial Cancer Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Endometrial Cancer Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Endometrial Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Context Therapeutics Inc., CooperSurgical Inc., Eisai Co., Ltd., Elekta AB, F. Hoffmann-La Roche AG, General Electric Company, GlaxoSmithKline PLC, Hologic Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Koninklijke Philips N.V., LiNA Medical ApS, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endometrial Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Chemotherapy
    • Immunotherapy
    • Radiation Therapy
  • Grade
    • Type I
    • Type II
  • End-User
    • Ambulatory Surgical Centers
    • Cancer Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Endometrial Cancer Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Endometrial Cancer Treatment Market?

3. What are the technology trends and regulatory frameworks in the Endometrial Cancer Treatment Market?

4. What is the market share of the leading vendors in the Endometrial Cancer Treatment Market?

5. Which modes and strategic moves are suitable for entering the Endometrial Cancer Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Endometrial Cancer Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevelance of type 1 and type 2 endometrial cancer worldwide
      • 5.1.1.2. Government initiatives to expand endometrial cancer treatment adoption
      • 5.1.1.3. Emergence of personalized and targeted uterine cancer therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement structure for endometrial treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to develop novel endometrial cancer treatments
      • 5.1.3.2. Favorable government approvals for endometrial cancer drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and risk associated with certain treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Endometrial Cancer Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy

7. Endometrial Cancer Treatment Market, by Grade

  • 7.1. Introduction
  • 7.2. Type I
  • 7.3. Type II

8. Endometrial Cancer Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cancer Centers
  • 8.4. Hospitals & Clinics

9. Americas Endometrial Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Endometrial Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Endometrial Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AstraZeneca PLC
    • 13.1.3. Bayer AG
    • 13.1.4. Becton, Dickinson and Company
    • 13.1.5. Boston Scientific Corporation
    • 13.1.6. Bristol-Myers Squibb Company
    • 13.1.7. Celgene Corporation
    • 13.1.8. Context Therapeutics Inc.
    • 13.1.9. CooperSurgical Inc.
    • 13.1.10. Eisai Co., Ltd.
    • 13.1.11. Elekta AB
    • 13.1.12. F. Hoffmann-La Roche AG
    • 13.1.13. General Electric Company
    • 13.1.14. GlaxoSmithKline PLC
    • 13.1.15. Hologic Inc.
    • 13.1.16. Johnson & Johnson Services, Inc.
    • 13.1.17. Karyopharm Therapeutics Inc.
    • 13.1.18. Koninklijke Philips N.V.
    • 13.1.19. LiNA Medical ApS
    • 13.1.20. Merck & Co., Inc.
    • 13.1.21. Novartis AG
    • 13.1.22. Pfizer Inc.
    • 13.1.23. Sanofi S.A.
    • 13.1.24. Siemens Healthineers AG
    • 13.1.25. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing